Fox Chase BR-076: Pembrolizumab in TNBC (Breast Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study is to see if the study drug, pembrolizumab, plus chemotherapy (carboplatin and gemcitabine) is safe and effective in treating people with metastatic triple negative breast cancer.
Triple Negative Metastatic Breast Cancer
Who Can Participate in the Study?
Adult women who :
- Have metastatic, triple negative breast cancer (spread to other parts of your body).
- Have already received up to 2 cancer therapies for their metastatic breast cancer
- Are candidates for chemotherapy with carboplatin and gemcitabine.
What is Involved?
If you join this study, you will be randomly put into a study group, like drawing numbers out of a hat.
- If you are in group 1, you will get pembrolizumab along with chemotherapy (carboplatin and gemcitabine).
- If you are in group 2, you will receive chemotherapy (carboplatin and gemcitabine) alone.
- You will have tests, exams, and procedures that are part of your standard of care and for study purposes.
- You will be asked to take the study drugs for up to 2 years. You will be followed until the study ends.